Document Detail

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
MedLine Citation:
PMID:  16423446     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Our objective was to develop a nomogram that predicts the probability of cancer-specific survival in men with untreated androgen-independent prostate cancer (AIPC). METHODS: AIPC was diagnosed in 129 consecutive patients between 1989 and 2002. No patient received cytotoxic chemotherapy. Univariate and multivariate Cox regression models were used to test the association between prostate-specific antigen (PSA) level at initiation of androgen deprivation, PSA doubling time (PSADT), PSA nadir on androgen deprivation therapy (ADT), time from ADT to AIPC, and AIPC-specific mortality. Multivariate regression coefficients were then used to develop a nomogram predicting AIPC-specific survival at 12-60 mo after AIPC diagnosis. Two-hundred bootstrap resamples were used to internally validate the nomogram. RESULTS: AIPC-specific mortality was recorded in 74 of 129 patients (57.4%). Other-cause mortality was recorded in 7 men (5.4%). Median overall survival was 52.0 mo (mean, 36.0 mo) and median AIPC-specific survival was 54.0 mo (mean, 35.0 mo). In univariate regression models, all variables were significant predictors of AIPC-specific survival (p < or = 0.02). In multivariate models, PSADT and time from androgen deprivation to AIPC remained statistically significant (p < or = 0.004). Bootstrap-corrected predictive accuracy of the nomogram was 80.9% versus 74.9% for our previous model. CONCLUSIONS: A nomogram predicting AIPC-specific survival is between 13% and 14% more accurate than previous nomograms and 6% more accurate than tree regression-based predictions obtained from the same data. Moreover, a nomogram approach combines several advantages, such as user-friendly interface and precise estimation of individual recurrence probability at several time points after AIPC diagnosis, which all patients deserve to know and all treating physicians need to know.
Robert Svatek; Pierre I Karakiewicz; Michael Shulman; Jose Karam; Paul Perrotte; Elie Benaim
Related Documents :
19836166 - Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radioth...
11113746 - A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors ...
16413696 - Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy...
10925096 - Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of ris...
21385286 - The impact of young age on outcomes in esophageal and junctional cancer.
24950776 - Determinants of repeat curative intent surgery in colorectal liver metastasis.
Publication Detail:
Type:  Journal Article     Date:  2006-01-06
Journal Detail:
Title:  European urology     Volume:  49     ISSN:  0302-2838     ISO Abbreviation:  Eur. Urol.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-13     Completed Date:  2007-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  666-74     Citation Subset:  IM    
Department of Urology, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd. J8.112, Dallas, Texas 75390-9110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgen Antagonists / therapeutic use*
Area Under Curve
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Proportional Hazards Models
Prostate-Specific Antigen / blood
Prostatic Neoplasms / blood,  drug therapy*,  mortality*,  pathology
ROC Curve
Retrospective Studies
Survival Analysis
Reg. No./Substance:
0/Androgen Antagonists; EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elective abortions for minors: impact of the new law in France.
Next Document:  Scalability of the surface-based DNA algorithm for 3-SAT.